A top global priority is to find agents that can stop the severe course of COVID-19 infection and consequently increase the chances of patient survival as rapidly as possible. Specific tests have shown that there are some promising drugs available, which have efficacy against the new coronavirus and have already been approved for the treatment of other diseases such as HIV and malaria. The World Health Organisation (WHO) has selected four particularly promising agents or agent combos for testing in a clinical trial programme that is being conducted across several countries. The DZIF and DZL have assumed the role of coordinating this Solidarity Trial in Germany. The trial is being supported by all German Centres for Health Research (DZG) and is being funded by the BMBF (Federal Ministry of Education and Research). (Image: BMBF)